Chronic Kidney Disease Clinical Trial
Official title:
Vitamin D Replacement in Chronic Kidney Disease and Its Effects on Iron Homeostasis, Serum Hepcidin, and Hemojuvelin Levels.
The purpose of the study is to learn more about how treatment with vitamin D can affect iron
metabolism and blood levels of two hormones that control iron levels, hepcidin and
hemojuvelin in people with chronic kidney disease (CKD).
Iron is an essential mineral which is a major component of proteins that carry oxygen in the
blood. Problems with iron metabolism can lead to low blood levels (anemia), which can
commonly happen in people with CKD.
New research over the last decade has uncovered a new hormone called `hepcidin', which is
made in the liver and released into the blood. Hepcidin controls how much iron is in the
blood by preventing the absorption of iron from food. Blood levels of hepcidin C are found
to be high in people with CKD, and a recent small study in people with normal kidney
function showed that treatment with vitamin D decreased hepcidin levels.
Another protein, known as `hemojuvelin', has been recently discovered and is also thought to
control the amount of iron in the blood. The relationship between vitamin D and hemojuvelin
has never been studied before.
In this study, investigators would like to examine the effects of vitamin D on iron
metabolism and blood levels of hepcidin C and hemojuvelin in individuals with CKD.
Iron homeostasis is tightly regulated in humans. Iron is mostly recycled from hemoglobin,
myoglobin and other enzymes. Since humans lack the capacity to excrete excess iron, it must
be intricately regulated at the site of its absorption in the duodenum and proximal jejunum.
In the last decade, hepcidin has emerged as a master regulator of iron homeostasis. It
decreases iron absorption from the gut mucosa by limiting its transport from the enterocyte
across the basolateral membrane into the circulation. It does so by down-regulating the
synthesis or promoting internalization of a basolateral membrane protein `Ferroportin', the
only known cellular iron exporter.
Vitamin D is hypothesized to exert a significant and independent effect on the iron
metabolism. In the CKD population, low vitamin-D levels independently correlate with the
severity of anemia. Hepcidin C levels are found to be elevated in the CKD population.
Mechanisms underlying the effect of vitamin D on iron homeostasis potentially include
vitamin D induced expression of erythropoietin receptors, increased proliferation of
erythroid precursors, and reduction in hepcidin C levels due to reduction in IL-6 from the
anti-inflammatory effects of vitamin D. More recently, a study revealed direct relationship
between vitamin D replacement and a sustained fall in hepcidin C levels. The same group of
researchers found the above relationship to be due to a direct effect of vitamin D on
hepcidin expression.
Hemojuvelin (HJV) is a protein encoded by the HFE2 gene and is found in the membrane bound
and the soluble form (sHJV) in the humans. Mutations in the HJV gene are responsible for
Juvenile Hemochromatosis. It is an upstream regulator of hepcidin transcription and appears
to be essential for hepcidin expression in the hepatocytes and has important role to play in
iron homeostasis. Recently, an assay has become available to measure the sHJV levels in the
serum.
Although, we know that hepcidin plays a central role in iron homeostasis and recent studies
have given us insight into the role hemojuvelin and vitamin D play in iron metabolism, to
date, no studies have examined the effect on vitamin D replacement on hepcidin, hemojuvelin
levels and iron metabolism in individuals with CKD.
Hypothesis 1: Treatment with an activated vitamin D analog in the individuals with CKD
results in a statistically significant fall in hepcidin C levels as compared to individuals
provided with placebo.
Hypothesis 2: Treatment with an activated vitamin D analog results in decreased levels of
soluble hemojuvelin in individuals with chronic kidney disease.
Hypothesis 3: Vitamin D replacement in the individuals with CKD results in improved iron
parameters as compared to the placebo.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |